Bayer Unveils Groundbreaking Pediatric Data for Investigational Low-Dose MRI Contrast Agent Gadoquatrane at RSNA 2025 Radiological Society of North America in Chicago, Bayer announced compelling new findings from the QUANTI Pediatric study—the first pediatric trial within its pivotal QUANTI clinical…
Johnson & Johnson and Naomi Watts Urge Women Over 40 to Embrace Eye Exams as a Foundational Act of Self-Care Johnson & Johnson Vision—a global leader in eye health—has joined forces with Academy Award–nominated actress, producer, entrepreneur, and women’s health…
Zoetis Unveils Strategic Vision for the Future of Animal Health at Innovation Webcast, Highlighting Robust R&D Pipeline and Multi-Billion-Dollar Growth Opportunities Zoetis Inc. the global leader in animal health, hosted a highly anticipated Innovation Webcast on December 3, 2025, at…
Janux Therapeutics Reports Encouraging Interim Phase 1 Data for JANX007 in mCRPC, Highlighting Strong Efficacy and Manageable Safety Profile Janux Therapeutics, Inc. a clinical-stage biopharmaceutical company pioneering novel immunotherapies through its proprietary platforms—Tumor Activated T Cell Engager (TRACTr), Tumor Activated…
Vistagen Appoints Nick Tressler as Chief Financial Officer, Strengthening Leadership Team Amid Growth and Clinical Milestones Vistagen Therapeutics, Inc. a late clinical-stage biopharmaceutical company focused on pioneering neuroscience innovations through nose-to-brain neurocircuitry, today announced the appointment of Nick Tressler as…
Omeros Corporation Announces Completion of Asset Purchase and License Agreement with Novo Nordisk for Zaltenibart a Late-Stage MASP-3 Inhibitor Omeros Corporation today announced the successful closing of its previously disclosed asset purchase and licensing transaction with Novo Nordisk, involving the…
Arrowhead Pharmaceuticals Reports Fiscal Year 2025 Financial Results and Highlights Major Regulatory and Clinical Milestones Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its financial results for the fiscal year ending September 30, 2025, alongside a comprehensive review of recent scientific,…
Allurion Unveils Initial Results on Program + Tirzepatide Combo Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR)—a global leader in innovative, non-surgical weight-loss technology—today announced encouraging initial results from a case series evaluating the impact of combining the Allurion…
Pathway to Cures Invests in SeraGene Therapeutics The fifth paragraph of the original release dated November 19, 2025, should read: Pathway to Cures joins Hextwo Capital as early investors in SeraGene Therapeutics.The fully updated and expanded release appears below. PATHWAY…
AstraZeneca Announces $2 Billion Expansion to Strengthen Maryland Manufacturing, Advance Innovation, and Support 2,600 Jobs AstraZeneca today unveiled a major strategic investment plan totaling $2 billion to expand its long-standing manufacturing presence in Maryland, further solidifying the state’s role as…
Parabilis Medicines Announces Compelling Preliminary Clinical Results for FOG-001 in Adamantinomatous Craniopharyngioma at SNO 2025 Parabilis Medicines, a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients with cancer, announced new preliminary clinical data highlighting the therapeutic promise of…
Quanterix Announces Comprehensive Board and Leadership Enhancements to Accelerate Its Next Phase of Strategic Growth Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a global leader in ultrasensitive biomarker detection and a pioneer in translating biomarker discoveries into impactful diagnostic…